What's Happening?
Genentech, a member of the Roche Group, announced positive results from its Phase III Krascendo 1 study, which evaluated the investigational drug divarasib against approved KRAS G12C inhibitors in patients with previously treated non-small cell lung cancer
(NSCLC). The study showed that divarasib achieved significant improvements in progression-free survival and overall survival compared to existing treatments, sotorasib and adagrasib. The safety profile of divarasib was consistent with previous data, with no new safety signals observed. The results suggest that divarasib could become a new standard of care for patients with KRAS G12C-mutant NSCLC, a subtype associated with poor prognosis.
Why It's Important?
The findings from the Krascendo 1 study are significant as they highlight divarasib's potential to improve clinical outcomes for patients with KRAS G12C-mutant NSCLC, a group that currently faces limited treatment options. The KRAS G12C mutation is prevalent in approximately 14% of NSCLC cases and is linked to aggressive disease progression. By demonstrating superior efficacy over existing treatments, divarasib could offer a more effective therapeutic option, potentially improving survival rates and quality of life for affected patients. This development also underscores the importance of precision medicine in addressing specific genetic mutations in cancer treatment.
What's Next?
Genentech plans to present the full data from the Krascendo 1 study at an upcoming medical meeting and submit the results to health authorities for regulatory approval. If approved, divarasib could be made available to patients with KRAS G12C-mutant NSCLC, providing a new treatment option. The company is also conducting additional Phase III trials to explore divarasib's efficacy in combination with other therapies, such as pembrolizumab, in different settings and lines of therapy. These efforts aim to expand the drug's applicability and further improve outcomes for lung cancer patients.
